Come visit Acarix at ACC Future Hub booth FH11

Acarix USA, Inc will be at the American College of Cardiology ACC congress in Washington DC 2-4APR 2022. We are launching our FDA cleared diagnostic rule-out aid for suspected CAD patients with stable chest pain: CADScor®System.
Did you know that approximately 9 out of 10 patients assessed for Coronary Artery Disease do not have CAD? Millions of patients present with chest pain and suspected CAD each year!

FDA cleared diagnostic rule-out aid for suspected Coronary Artery Disease in patients with stable chest pain

Learn more about our innovative, FDA cleared, AI-powered CAD diagnostic aid at the ACC22, Future Hub booth FH11.
CADScor®System offers a simple, non-invasive aid to help rule out more than one third of these patients, potentially helping your team focus on the true root cause of symptoms, freeing up capacity for patients who need care, and decide on the next steps of the diagnostic pathway.

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit